![]()
17
| 1 | 2009
Klinisk Biokemi i Norden
matic disorders: In Hochberg MC, Silman
AJ, Smolen JS, Weinblatt ME, Weisman MH,
editors. Rheumatology, 4th edition, Mosby,
Edinburgh 2008, pp 215-26.
[11] Arbuckle MR, McClain MT, Rubertone
MV, Scofield RH, Dennis GJ, James JA et
al. Development of autoantibodies before the
onset of systemic lupus erythematosus. N Eng
J Med 2003; 349:1526-33.
[12] Kallenberg CGM, Wouda AA, Hoet MH, van
Venrooij WJ Development of connective tissue
disease in patients presenting with Raynaud’s
phenomena: a six year follow-up with emp-
hasis on the value of antinuclear antibodies as
detected by immunoblotting. Ann Rheum Dis
1988; 47:634-41,
[13] Meyer OC, Fertig N, Lucas M, Somogyi N,
Medsger TA Jr. Disease subsets, antinuclear
antibody profile, and clinical features in 127
French and 247 US adult patients with syste-
mic sclerosis. J Rheumatol 2007; 34:104-9.
[14] Koenig M, Fritzler MJ, Targoff IN, Troyanov Y,
Senécal J-L. Heterogeneity of autoantibodies
in 100 patients with autoimmune myositis:
insights into clinical features and outcomes.
Arthritis Res Ther 2007; 9(4): R78.
[15] Smolen JS, Butcher B, Fritzler MJ, Gordon T,
Hardin J, Kalden JR. Reference sera for antinu-
clear antibodies. II. Further definition of anti-
body specificities in international reference
sera by immunofluorescence and western blot-
ting. Arthritis Rheum 1997; 40: 413-8.
[16] Pincus T, Schur PH, Rose N, Decker JL, Talal
N. Measurement of serum DNA activity in
SLE. N Engl J Med 1971; 281: 701-5.
[17] Swaak T, Smeenk R. Detection of anti-dsDNA
as a diagnostic tool: a prospective study in 441
non-systemic lupus erythematosus patients
with anti-dsDNA antibody (anti-dsDNA).
Ann Rheum Dis 1985;44:245-51.
[18] Riboldi P, Gerosa M, Moroni G, Radice A,
Allegri F, Sinico A et al. Anti-DNA antibo-
dies: a diagnostic and prognostic tool for
systemic lupus erythematosus? Autoimmunity
2005;38:39-45.
[19] Rekvig OP, Nossent JC. Anti-double stran-
ded DNA antibodies, nucleosomes, and sys-
temic lupus erythematosus. Arthritis Rheum
2003;48:300-12.
[20] Bizzaro N, Wiik A: Appropriateness in anti-
nuclear antibody testing: from clinical request
to strategic laboratory practice. Clin Exp
Rheumatol 2004;22:349-55.
[21] Fritzler MJ, Wiik A, Fritzler ML, Barr SG. The
use and abuse of commercial kits to detect
autantibodies. Arthritis Res Ther 2003; 5:192-
201.
Review.
[22] Fritzler MJ. Challenges to the use of autoanti-
bodies as predictors of disease onset, diagnosis
and outcomes. Autoimmun Rev 2008;7:616-20.
Review.
[23] Ramos PS, Kelly JA, Gray-McGuire C, Bruner
GR, Leiran AN, Meyer CM et al. Familial aggre-
gation and linkage analysis of autoantibody
traits in pedigrees multiplex for systemic lupus
erythematosus. Genes Immun 2006; 7: 417-32.
[24] Bayer PM, Bauerfeind S, Bienvenu J, Fabien
N, Frei C, Gilburd B, Heide KG, Høier-
Madsen M, Meroni PL, Monier JC, Monneret
G, Panzeri P, Shoenfeld Y, Spertini F, WiikA:
Multicenter evaluation study on a new HEp2
ANA screening enzyme immune assay.
J Autoimmun 1999;13:89-93.
[25] FengerM,WiikA,Høier-MadsenM, Lykkegaard
JJ, Rozenfeld T, Hansen MS, Samsoe BD,
Jacobsen S: Detection of antinuclear antibodies
by solid-phase immunoassays and immunofluo-
rescence analysis. Clin Chem 2004;50:2141-7.
[26] Sherer Y, Gorstein A, Fritzler MJ, Shoenfeld.
Autoantibody explosion in systemic lupus eryt-
hematosus: more 100 different autoantibodies
found in SLE patients. Semin Arthritis Rheum
2004;34:501-37.
[27] Strandberg L, Winqvist O, Sonesson SE,
Mohseni S, Salomonsson S, Bremme K et al.
Antibodies to amino acid 200-239 (p200) of
Ro52 as serological markers for for the risk of
developing congenital heart block. Clin Exp
Immunol 2008;154: 30-7.
[28] Flisiak R, PelszynskaM, Prokopowitcz, Rogolske
M, Grygoruk U. High concentration of antimi-
tochondrial antibodies predicts primary bili-
ary cirrhosis. World J Gastroenterol 2005; 11:
5706-9.
